首页> Journal of cancer research and therapeutics> PD-1 inhibitor monotherapy versus combination therapy: A real-world study of patients with recurrent or metastatic advanced esophageal squamous cell carcinoma after first-line chemotherapy.

PD-1 inhibitor monotherapy versus combination therapy: A real-world study of patients with recurrent or metastatic advanced esophageal squamous cell carcinoma after first-line chemotherapy.

导出 LinkOut

翻译打印收藏纠错

第一作者： Guanli,Yang

第一单位： Department of Radiation Oncology, Shandong Cancer Hospital, Cheeloo College of Medicine, Shandong University; Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.

作者： Guanli,Yang ^[1] ; Hongfu,Sun ^[1] ; Chunyang,Zhou ^[2] ; Nini,Sun ^[3] ; Lixia,Xu ^[4] ; Wei,Huang ^[1] ; Baosheng,Li ^[1]

作者单位： Department of Radiation Oncology, Shandong Cancer Hospital, Cheeloo College of Medicine, Shandong University; Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China. ^[1] Department of Radiation Oncology, Shandong Cancer Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China. ^[2] Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China. ^[3] Department of Radiation Oncology, the Zhangqiu District People's Hospital of Jinan, Shandong, China. ^[4]

关键词 Anti-angiogenesis targeted therapy Chemotherapy Esophageal squamous cell carcinoma Immunotherapy

医学主题词抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);食管肿瘤(Esophageal Neoplasms);人类(Humans);回顾性研究(Retrospective Studies)

DOI 10.4103/jcrt.jcrt_125_22

PMID 35645126

发布时间 2022-06-03

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交